Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

被引：9

作者：

Dal, Mehmet Sinan ^{[1
,2
]}

Ulu, Bahar Uncu ^{[1
,2
]}

Uzay, Ant ^{[3
]}

Akay, Olga Meltem ^{[4
]}

Besisik, Sevgi ^{[5
]}

Yenerel, Mustafa Nuri ^{[5
]}

Celik, Serhat ^{[6
]}

Kaynar, Leylagul ^{[7
]}

Yucel, Orhan Kemal ^{[8
]}

Deveci, Burak ^{[9
]}

Sonmez, Mehmet ^{[10
]}

Mehtap, Ozgur ^{[11
]}

Bekoz, Huseyin Saffet ^{[7
]}

Sunu, Cenk ^{[12
]}

Salim, Ozan ^{[8
]}

Ulas, Turgay ^{[13
]}

Karti, Sami ^{[3
]}

Altuntas, Fevzi ^{[1
,2
,14
]}

Ferhanoglu, Burhan ^{[15
,16
]}

Tuglular, Tulin Firat ^{[17
]}

机构：

[1] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Div Hematol, TR-06200 Ankara, Turkey

[2] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Bone Marrow Transplantat Unit, TR-06200 Ankara, Turkey

[3] Acibadem Univ, Atakent Hosp, Hematol & Bone Marrow Transplant Unit, Istanbul, Turkey

[4] Koc Univ, Dept Internal Med, Div Hematol, Med Sch, Istanbul, Turkey

[5] Istanbul Univ, Istanbul Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkey

[6] Erciyes Univ, Dept Internal Med, Div Hematol, Kayseri, Turkey

[7] Istanbul Medipol Univ, Dept Internal Med, Div Hematol, Istanbul, Turkey

[8] Akdeniz Univ, Fac Med, Dept Internal Med, Div Hematol, Antalya, Turkey

[9] Medstar Antalya Hosp, Hematol & Stem Cell Transplantat Unit, Antalya, Turkey

[10] Karadeniz Tech Univ, Dept Internal Med, Div Hematol, Trabzon, Turkey

[11] Kocaeli Univ, Fac Med, Dept Internal Med, Div Hematol, Kocaeli, Turkey

[12] Sakarya Univ, Fac Med, Dept Internal Med, Div Hematol, Sakarya, Turkey

[13] Near East Univ, Sch Med, Dept Internal Med, Div Hematol, Nicosia, Cyprus

[14] Ankara Yildirim Beyazit Univ, Sch Med, Dept Internal Med, Div Hematol, Ankara, Turkey

[15] Koc Univ, Sch Med, Dept Internal Med, Div Hematol, Istanbul, Turkey

[16] VKV Amer Hosp, Istanbul, Turkey

[17] Marmara Univ, Dept Internal Med, Div Hematol, Istanbul, Turkey

来源：

ANNALS OF HEMATOLOGY | 2023年 / 102卷 / 01期

关键词：

Diffuse large B-cell lymphoma; Polatuzumab vedotin; Refractory; Relapsed; Rituximab; Bendamustine; ANTIBODY-DRUG CONJUGATE; NON-HODGKIN-LYMPHOMA; PLUS BENDAMUSTINE; SURVIVAL; SAFETY;

D O I：

10.1007/s00277-022-05052-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m(2) on day 1, and bendamustine 90 mg/m(2) on days 1-2 of each cycle. Median age at Pola-BR initiation was 55 (19-84). The overall response rate was 47.9%, including 32.4% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3-4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.

引用

页码：133 / 140

页数：8

共 22 条

[1]

[Anonymous], 2020, POLIVY PRESCRIBINGIN

[2] Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study [J].

Arcari, Annalisa ;

Chiappella, Annalisa ;

Spina, Michele ;

Zanlari, Luca ;

Bernuzzi, Patrizia ;

Valenti, Vanessa ;

Tani, Monica ;

Marasca, Roberto ;

Cabras, Maria Giuseppina ;

Zambello, Renato ;

Santagostino, Alberto ;

Ilariucci, Fiorella ;

Carli, Giuseppe ;

Musto, Pellegrino ;

Savini, Paolo ;

Marino, Dario ;

Ghio, Francesco ;

Gentile, Massimo ;

Cox, Maria Christina ;

Vallisa, Daniele .

LEUKEMIA & LYMPHOMA, 2016, 57 (08) :1823-1830

[3] New approach to classifying non-hodgkin's lymphomas: Clinical features of the major histologic subtypes [J].

Armitage, JO ;

Weisenburger, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2780-2795

[4] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[6] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [J].

Crump, Michael ;

Neelapu, Sattva S. ;

Farooq, Umar ;

Van den Neste, Eric ;

Kuruvilla, John ;

Westin, Jason ;

Link, Brian K. ;

Hay, Annette ;

Cerhan, James R. ;

Zhu, Liting ;

Boussetta, Sami ;

Feng, Lei ;

Maurer, Matthew J. ;

Navale, Lynn ;

Wiezorek, Jeff ;

Go, William Y. ;

Gisselbrecht, Christian .

BLOOD, 2017, 130 (16) :1800-1808

[7] Polatuzumab Vedotin: First Global Approval [J].

Deeks, Emma D. .

DRUGS, 2019, 79 (13) :1467-1475

[8] Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas [J].

Dimou, Maria ;

Papageorgiou, Sotirios G. ;

Stavroyianni, Niki ;

Katodritou, Eirini ;

Tsirogianni, Maria ;

Kalpadakis, Christina ;

Banti, Anastasia ;

Arapaki, Maria ;

Iliakis, Theodoros ;

Bouzani, Maria ;

Verrou, Eugenia ;

Spanoudakis, Emmanouil ;

Giannouli, Stavroula ;

Marinakis, Theodoros ;

Mandala, Evdokia ;

Mparmparousi, Despoina ;

Sachanas, Sotirios ;

Dalekou-Tsolakou, Maria ;

Hatzimichael, Eleftheria ;

Vadikolia, Chryssa ;

Violaki, Vasiliki ;

Poziopoulos, Christos ;

Tsirkinidis, Pantelis ;

Chatzileontiadou, Sofia ;

Vervessou, Elissavet ;

Ximeri, Maria ;

Sioni, Anastasia ;

Konstantinidou, Pavlina ;

Kyrtsonis, Marie-Christine ;

Siakantaris, Marina P. ;

Angelopoulou, Maria K. ;

Pappa, Vassiliki ;

Konstantopoulos, Kostas ;

Panayiotidis, Panayiotis ;

Vassilakopoulos, Theodoros P. .

HEMATOLOGICAL ONCOLOGY, 2021, 39 (03) :336-348

[9] Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma [J].

Dornan, David ;

Bennett, Fiona ;

Chen, Yvonne ;

Dennis, Mark ;

Eaton, Dan ;

Elkins, Kristi ;

French, Dorothy ;

Go, Mary Ann T. ;

Jack, Andrew ;

Junutula, Jagath R. ;

Koeppen, Hartmut ;

Lau, Jeffrey ;

McBride, Jacqueline ;

Rawstron, Andy ;

Shi, Xiaoyan ;

Yu, Nancy ;

Yu, Shang-Fan ;

Yue, Peng ;

Zheng, Bing ;

Ebens, Allen ;

Polson, Andrew G. .

BLOOD, 2009, 114 (13) :2721-2729

[10]

European Commission approves Roche's Polivy for people with previously treated aggressive lymphoma, 2020, EUR COMM APPR ROCH P

← 1 2 3 →